3 completed, 2 terminated, 1 unknown. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Lpath, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers 0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab - Healthy Subjects | Phase 1 | Completed | Lpath, Inc. | 36 | 2015-09-01 | 2016-05-06 |
| A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma ASONEP - Renal Cell Carcinoma | Phase 2 | Terminated | Lpath, Inc. | 40 | 2013-02-01 | 2016-01-20 |
| Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea - Exudative Age-related Macular Degeneration | Phase 2 | Completed | Lpath, Inc. | 158 | 2012-08-01 | 2016-10-17 |
| iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) iSONEP (sonepcizumab/LT1009) - Pigment Epithelial Detachment | Phase 1 | Terminated | Lpath, Inc. | 12 | 2011-03-01 | 2013-04-23 |
| Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration iSONEP - Neovascular Age Related Macular Degeneration | Phase 1 | Unknown | Lpath, Inc. | 15 | 2008-10-01 | 2012-04-16 |
| Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors ASONEP (sonepcizumab/LT1009) - Solid Tumors | Phase 1 | Completed | Lpath, Inc. | 37 | 2008-04-01 | 2012-01-31 |
Carcinoma, Renal Cell (1) · Choroidal Neovascularization (1) · Macular Degeneration (1) · Neoplasms (1) · Polypoidal Choroidal Vasculopathy (1) · Retinal Detachment (1)
sonepcizumab (5) · Bevacizumab (1) · Infusions, Intravenous (1) · Ranibizumab (1) · Saline Solution (1) · aflibercept (1) · salicylhydroxamic acid (1)
United States (6)
Dario A Paggiarino, MD (2) · Glenn Stoller, MD (2) · Susan Hazel (1) · William Garland, PhD (1)